A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
Public ClinicalTrials.gov record NCT02967692. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to evaluate safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with BRAF V600 mutant, unresectable and metastatic melanoma.
Study identification
- NCT ID
- NCT02967692
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 568 participants
Conditions and interventions
Conditions
Interventions
- Spartalizumab Biological
- Placebo Other
- Dabrafenib Drug
- Trametinib Drug
Biological · Other · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 17, 2017 (Actual)
- Primary completion
- Aug 11, 2020 (Actual)
- Completion
- Aug 21, 2024 (Actual)
- Last update posted
- Sep 18, 2025
2017 – 2024
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Cancer Associates for Research and Excellence | Encinitas | California | 92024 | — |
| UC Irvine Medical Center | Orange | California | 92613-4091 | — |
| California Pacific Medical Center | San Francisco | California | 94115 | — |
| Stanford Cancer Center | Stanford | California | 94305 | — |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| Johns Hopkins U | Lutherville | Maryland | 21093 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| NYU Laura and Isaac Perlmutter Cancer Center | New York | New York | 10016 | — |
| University of Pittsburgh Med Center | Pittsburgh | Pennsylvania | 15213 | — |
| University of Tennessee Medical Ctr | Knoxville | Tennessee | 37920 | — |
| Univ of TX MD Anderson Cancer Cntr | Houston | Texas | 77030 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 167 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02967692, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 18, 2025 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02967692 live on ClinicalTrials.gov.